Ad Astra Awards
Ad Astra Journal
Science library
White book
University rankings
Who's who
Publications
Theses and dissertations
Ad Astra association
 
Press releases
News
Events
Funding opportunities
 
Login
Registration
 
>> Românã
 
   
 

Eugeniu Banu

Spitalul Sf-Constantin, Departamentul Oncologie Medicala, Brasov, Romania

Institution web page: http://spitalulsfconstantin.ro/
Send email

Born: 1967

Interests: medical oncology, clinical trials, biostatistics, informatics

Details:
Head of Medical Oncology Department, Saint Constantin Private Hospital, Brasov, Romania

Full member of the European Society for Medical Oncology (ESMO)
· European Association for Cancer Research (EACR)
· International Gynecologic Cancer Society (IGCS)
· European Association of Urology (EAU)
· European Society of Gynaecological Oncology (ESGO)
· International Association for the Study of Lung Cancer (IASLC)
· Society for Translational Oncology (STO)
· International Society of Gastrointestinal Oncology (ISGO)
· European Society of Breast Cancer Specialists (EUSOMA)
· European Society of Digestive Oncology (ESDO)
· American Statistical Association (ASA)
· Royal Statistical Society (RSS)
· International Society for Clinical Biostatistics (ISCB)
· World Oncology Network (WON)
· National Cervical (NCCC) and Prostate Cancer (NPCC) Coalition
· IRMA (Renal Insufficiency and Cancer Medications) Study Group

Active member (consulting services):
o Gerson Lehrman Group Healthcare Councilsa
o Medefield® Healthcare Advisory Board
o Omnimed Santé Kantar Health Panel®
o Guidepoint Global Advisors®

· Medical Reviewer for 10 peer-review journals in oncology (56 reviewed articles): Journal of Clinical Oncology (since April 2006), Annals of Oncology (May 2007), Contemporary Clinical Trials (November 2007), Cancer (May 2008), American Journal of Clinical Oncology (June 2008), Gynecologic Oncology and International Journal of Clinical Practice (August 2008), Journal of Experimental & Clinical Cancer Research (March 2010), Journal of Men�s Health (July 2010), The Open Lung Cancer Journal (November 2010)

Selected publications:
• Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA. . Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. . Radiology 2010, 256(2), pp. 511-518, 2010.
• Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?. BJU Int , Feb 6. [Epub ahead of print], 2009.
• Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int , Feb 6. [Epub ahead of print], 2009.
• Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S. . Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. . Eur Urol, 55(5), p. January 13, 2009.
• Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S. . Platelet microparticles: a potential predictive factor of overall survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol, 2008 June 20 [Epub ahead of print), 55(4), 2009.
• Berhoune M, Banu E, Scotte F, Prognon P, Oudard S, Bonan B. . Therapeutic strategy for treatment of metastatic non-small cell lung cancer. . Ann Pharmacother, 42(11), October 28 [Epub ahead of print), pp. 1640-1652, 2008.
• Riquet M, Cazes A, Pfeuty K, Ngabou UD, Foucault C, Dujon A, Banu E. . Multiple lung cancers prognosis: what about histology? . Ann Thorac Surg, 86(3), pp. 921-926, 2008.
• Marc Riquet, Patrick Bagan, EugenIu Banu. Reply. Ann Thorac Surg, 86(1), p. 354, 2008.
• Assouad J, Banu E, Brian E, Pham DN, Dujon A, Foucault C, Riquet M. Strategies and outcomes in pulmonary and extrapulmonary metastases from renal cell cancer. Eur J Cardiothorac Surg, 33(5), pp. 794-798, 2008.
• Scotté F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Tourani JM, Andrieu JM, Oudard S. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer, 112(7), pp. 1625-1631, 2008.
• S. Oudard, E. Banu, I. Latorzeff, A. Caty, L. Miglianico, F. Rolland, F. Priou, M. Mourey, P. Beuzeboc, S. Culine. Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +/-docetaxel. In Proceedings of Genitourinary Cancers Symposium, 14-16 February, San Francisco. 2008.
• Medioni J, Dionysopoulos D, Banu E, Scotté F, Beuzeboc P, Oudard S. Chemotherapy for prostate cancer. Presse Med, 37(5Pt2), pp. 814-820, 2007.
• Marc Riquet, Patrick Bagan, Françoise Le Pimpec Barthes, Eugeniu Banu, Florian Scotte, Christophe Foucault, Antoine Dujon, Claire Danel. Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases. Ann Thorac Surg, 84(6), pp. 1818-1824, 2007.
• Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, Andrieu JM, Oudard S. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or/and metastatic pancreatic cancer. Drugs Aging, 24(10), pp. 865-879, 2007.
• S Oudard, E Banu, F Scotte, A Banu, J Medioni, P Beuzeboc, F Joly, J-M Ferrero, F Goldwasser and J-M Andrieu. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Annals of Oncology, 18(11), pp. 1828-1833, 2007.
• A. Banu, E. Banu, D. Dionysopoulos, J. Medioni, F. Scotte, E. Levy and S. Oudard. Chromogranine A and neuron-specific enolase as the main predictors of survival for hormone-refractory prostate cancer (HRPC) patients. In Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Abstract 15594, No 18S (June 20 Supplement), 25. 2007.
• E. Banu, F. Scotte, A. Banu, J. Medioni, M. Brizard, E. Levy and S. Oudard. Is the natural history of prostate cancer different according to serum neuroendocrine profile?. In Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Abstract 15536, No 18S (June 20 Supplement), 25. 2007.
• Banu E, Banu A, Medioni J, Levy E, Thiounn N, Mejean A, Andrieu JM, Oudard S. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: Modelization using a standardized set of response criteria. The Prostate, 67 (14), pp. 1543-1549, 2007.
• Oudard S, Banu E, Scotte F, Beuzeboc P, Guyader C, Medioni J. New targeted therapies in hormone-refractory prostate cancer. Bull Cancer, 94(6), pp. F62-68, 2007.
• Helley D, Banu E, Bouziane A, Banu A, Oudard S, Fischer A. M. Platelet microparticles are a predictive factor of overall survival in patients with prostate cancer. In The XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 6-12 July, 2007:2411, PS 525. 2007.
• S. Oudard, J. Medioni, A. Chedid, E. Banu, D. Dionysopoulos, J. Balcaceres, F. Scotté. Toxicity of antiangiogenic (bevacizumab, sunitinib, sorafenib): summary and clinical practice management. La Lettre du Cancérologue, XVI(5), pp. 191-194, 2007.
• Medioni J, Cojocarasu O, Banu E, Cassar-Queudeville A, Halimi P, Oudard S. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targeted Oncology, 2 (3), pp. 193-195, 2007.
• Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S. Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: Results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) Study. The Journal of Urology, Vol. 177, Issue 5, pp. 1698-1702, 2007.
• A. Banu, D. Helley, E. Banu, A. M. Fischer, F. Scotte, A. Bouziane, S. Oudard. Platelet microparticles (PMP): A predictive factor of overall survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy. Poster presentation. Abstract 4639. J Clin Oncol (supplement) 2006; 24(18S):251s, 2006.
• J. Ayllon, S. Oudard, E. Banu, J. L. Janneau, D. Helley, S. Richon, A. Banu, E. Levy, J. Medioni, D. Bellet. Early placenta insuline-like peptide (pro-EPIL): A novel biomarker in advanced and metastatic non-small cell lung cancer (NSCLC) patients treated by chemotherapy. Abstract 20069. J Clin Oncol (supplement) 2006; 24(18S):706s. , 2006.
• E. Banu, O. Rixe, C. Linassier, J. P. Machiels, M. Baudard, F. Ringeisen, T. Velu, M. A. Lefrere-Belda, J. M. Limacher, S. Oudard. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). Poster presentation. Abstract 2581. J Clin Oncol (supplement) 2006; 24(18S):120s. , 2006.
• J. Ayllon, V. Plazanet, E. Fabre Guillevin, E. Banu, B. Bonan, S. Oudard, F. Le Pimpec Barthes, N. Theou, H. Sors and J. M. Andrieu. Optimum timing of gefitinib therapy in metastatic non-small cell lung cancer (NSCLC) patients. In Abstract 7323. J Clin Oncol (supplement) 2005; 23(16S):700s. . 2005.
• A. Vieillefond, P. Beuzeboc, L. Mignot, E. Banu, F. Priou, E. Malaurie, P. Dalivoust, X. Muracciole, M. Sibony and S. Oudard. HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab. Abstract 4700. J Clin Oncol (supplement) 2005; 23(16S):427s. , 2005.
• P. Beuzeboc, E. Banu, Y. Goubely Brewer, A. Banu, M. Zerbib, T. Flam, M. Peyromaure, F. Scotte, J. M. Andrieu and S. Oudard. Corrected area under prostate-specific antigen (PSA) curve and PSA half-time dynamics during chemotherapy. A new prognostic classification for hormone-refractory prostate cancer (HRPC) patients. In Poster presentation. Abstract 4641. J Clin Oncol (supplement) 2005; 23(16S):413s. . 2005.
• A. Banu, S. Oudard, E. Banu, D. Kamioneur, M. Housset, N. Thiounn, F. Scotte, A. Jenabian, A. Mejean, J. M. Andrieu. Combination of prostate-specific antigen (PSA) exposure and Gleason score as prognostic factors for prostate cancer (PC) patients. Poster presentation. Abstract 73. Proceedings of Prostate Cancer Symposium, 17 February, Orlando, Florida 2005:70. , 2005.
• S. Oudard, E. Banu, A. Banu, F. Scotte, E. Levy, J. Medioni, E. Fabre Guillevin, J. Ayllon, N. Arakelyan, J. M. Andrieu. Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results. Poster presentation. Abstract 4634. J Clin Oncol (supplement) 2005; 23(16S):411s. , 2005.
• E. Banu, S. Oudard, A. Banu, A. Fodor, B. Landi, T. Lecomte, P. Laurent-Puig, P. H. Cugnenc, J. M. Andrieu. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC). Poster presentation. Abstract 4101. J Clin Oncol (supplement) 2005; 23(16S):333s. , 2005.
• S, Oudard S, Duclos B, Banu E, Priou F, Rousseau F, Langlois D, Banu A, Rolland F. A phase II prospective study of gemcitabine and platinum-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study. Poster discussion. Abstract 4543. J Clin Oncol (supplement) 2005; 23(16S):390s. , 2005.
• Scotte F, Banu E, Oudard S, Banu A, Medioni J, Fabre-Guillevin E, Mejean A, Fontaine E, Thiounn N, Andrieu JM. Prostate-specific antigen doubling-time (PSA DT) before onset of chemotherapy as survival predictor for hormone refractory prostate cancer (HRPC) patients. Poster discussion. Abstract 4551. J Clin Oncol (supplement) 2005; 23(16S):390s. , 2005.
• Banu E, Oudard S, Levy E, Fabre-Guillevin E, Banu A, Ayllon J, Scotte F, Fodor A, Andrieu JM. CA 125 dynamics during lifetime as prognostic factor for ovarian cancer (OC) patients. In Abstract 94O. Poster and oral presentation. ESMO Scientific and Educational Conference, June 2-5, Budapest. . Educational and Abstract Book 2005; 16, supplement 2, ii296, 2005.
• Oudard S, Medioni J, Scotte F, Banu E. Prostate cancer: update. Bulletin du Cancer, 92, pp. 865-873, 2005.
• Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S. Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand. Journal of Clinical Oncology, 23, pp. 4424-4429, 2005.
• Oudard, S, Banu, E, Beuzeboc, P, Eric Voog, Louis Marie Dourthe, Anne Claire Hardy-Bessard, Claude Linassier, Florian Scotté, Adela Banu, Yvan Coscas, François Guinet, Marie-France Poupon, Jean-Marie Andrieu. Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 23, pp. 3343-3351, 2005.
• S. Oudard, E. Banu, N. Thiounn, M. Zerbib, T. Flam, B. Debré, A. Banu, F. Scotté and J. -M. M. Andrieu. Corrected area under serum PSA curve as a predictor of survival after chemotherapy for hormone-refractory prostate cancer (HRPC) patients. In Poster presentation. Abstract 9579. J Clin Oncol (supplement) 2004; 22(14S):850. . 2004.
• E. Banu, M. Levee, F. Scotte, A. Banu, S. Oudard, J. Ayllon, C. Le Maignan, B. Bonan, A. L. Le Louet, J. M. Andrieu. Corrected area under serum hemoglobin curve (Hb c-AUC) as a predictor of maximal hemoglobin response after erythropoietin (rHuEpo) treatment in chemotherapy induced anemia patients. Poster presentation. Abstract 9586. J Clin Oncol (supplement) 2004; 22(14S):852. , 2004.
• Le Frè re-Belda MA, Banu E, Badoual C, Oudard. Etude de l’expression du récepteur du facteur de croissance épithélial R-EGF dans le cancer de la prostate et corrélations cliniques. In Ann Pathol (suppl), 23, p. IS114. 2003.
• S. Oudard, E. Banu, A. Banu, F. Scotte, E. Levy, C. Maignan, J. Andrieu. Prostate-specific antigen half-time (PSAHT) as a predictor of survival for hormone-refractory prostate cancer (HRPC): A standardized set of response criteria. In Poster presentation. Abstract 1673. Proc Am Soc Clin Oncol 2003; 22:416. . 2003.
• Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, Delattre JY. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. Journal of Neurooncology, 63, pp. 81-86, 2003.
• Ciuleanu TE, Curca R, Iancu D, Todor N, Cebotaru C, Radulescu I, Banu E, Ghilezan N. First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study. J Buon, 7(1), pp. 43-46, 2002.
• Cebotaru C, Ghilezan N, Todor N, Popa L, Iancu D, Cainap C, Banu E, Eniu A, Mihailov A, Homokos H, Ciuleanu TE. Gemcitabine in Combination with «De Gramont» Protocol as First-Line Chemotherapy for Unresectable or Metastatic Pancreatic Carcinoma. A phase II study. Radioterapie & Oncologie Medicala, VII(1), pp. 77-84, 2001.
• Mihailov A, Ciuleanu TE, Todor N, Curca R, Iancu D, Taju N, Cebotaru C, Radulescu I, Neacsu C, Eniu A, Cainap C, Banu E, Homokos H, Ghilezan N. . A phase II trial of Vinorelbine and Cisplatin (VP) in stage IIIB non-small cell lung cancer (NSCLC). Radioterapie & Oncologie Medicala, VII(2), pp. 158-162, 2001.
• Zdrenghea, D, Banu, E, Bogdan, E, Beudean M. The effect of low-dose amiodarone in prevention of paroxysmal atrial fibrillation. Rom J Intern Med, 34, pp. 199-204, 1996.

Publications from the ISI database, indexed between 2002-2011, produced in Romania:
• Ciuleanu, TE; Curca, R; Iancu, D; Todor, N; Cebotaru, C; Radulescu, IL; Banu, E; Ghilezan, N, Topotecan and etoposide first line chemotherapy of advanced small cell lung cancer. A phase II study. INTERNATIONAL JOURNAL OF CANCER, , p. 437, 2002.
More information


Back

   
© Ad Astra 2001-2013